Artificial intelligence (AI) software developer Optellum has received $14 million (15 million euros) in a series A funding round.
The financing round was led by lead investor Mercia, along with additional investors Intuitive Venture and Black Opal Ventures. Existing investors St. John's College in the University of Oxford, IQ Capital, and the family office of Sir Martin & Lady Audrey Wood also participated in the round, according to the vendor.
Optellum said it would use the funds to scale its base, operations, and commercial launches in the U.K. and U.S. for its lung health AI platform, as well as to invest further in research and development. In addition, the firm also plans to apply its technology to integrate imaging data with molecular data, robotics, and liquid biopsies in order to expand its platform into the domain of personalized therapy decisions.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
